Showing results (11-20 of 920) with videos related to
Sort By:
Pageof 92
Hepatology International|August 28, 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLDMingqian Jiang, Ziyan Pan, Jacob George, et al.Journal of Viral Hepatitis|July 16, 2026
Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023Maito Suoh, Saeed Esmaili, Mohammed Eslam, et al.Hepatology International|October 16, 2024
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver researchMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.World Journal of Gastroenterology|November 14, 2013
Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infectionMohammed Eslam, David R Booth, Jacob George, et al.Frontiers in Bioscience (Landmark Edition)|April 29, 2024
A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune CellsZiyan Pan, Jawaher Alharthi, Ali Bayoumi, et al.Plos One|May 9, 2024
Exportin 4 DNA promoter methylation in liver fibrosisZiyan Pan, Ali Bayoumi, Mayada Metwally, et al.Journal of Digestive Diseases|December 13, 2021
The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis CAhmed Al-Omary, Karen Byth, Martin Weltman, et al.Hepatology International|June 20, 2024
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptationMohammad Alarabi, Ziyan Pan, Manuel Romero-Gómez, et al.Clinical and Molecular Hepatology|November 10, 2021
MAFLD enhances clinical practice for liver disease in the Asia-Pacific regionTakumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.Hepatology International|December 21, 2023
Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?Mariana Michelle Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, et al.Pageof 92